LALPATHLAB - Technical Analysis with Chart Patterns & Indicators
Back to ListTechnical Rating: 4.1
| Stock Code | LALPATHLAB | Market Cap | 27,303 Cr. | Current Price | 1,624 ₹ | High / Low | 1,771 ₹ |
| Stock P/E | 51.4 | Book Value | 148 ₹ | Dividend Yield | 0.87 % | ROCE | 29.4 % |
| ROE | 23.1 % | Face Value | 10.0 ₹ | DMA 50 | 1,510 ₹ | DMA 200 | 1,472 ₹ |
| Chg in FII Hold | -3.11 % | Chg in DII Hold | 2.17 % | PAT Qtr | 141 Cr. | PAT Prev Qtr | 113 Cr. |
| RSI | 57.1 | MACD | 50.4 | Volume | 2,09,006 | Avg Vol 1Wk | 2,78,218 |
| Low price | 1,272 ₹ | High price | 1,771 ₹ | PEG Ratio | 2.32 | Debt to equity | 0.08 |
| 52w Index | 70.6 % | Qtr Profit Var | -4.92 % | EPS | 30.3 ₹ | Industry PE | 43.9 |
📈 Chart & Trend Analysis: LALPATHLAB is trading at ₹1,624, above both its 50 DMA (₹1,510) and 200 DMA (₹1,472), confirming bullish momentum. RSI at 57.1 indicates healthy momentum without being overbought. MACD at 50.4 shows strong positive divergence. Bollinger Bands place price near the upper band, suggesting continued strength but with volatility risk.
🔎 Momentum Signals: Current volume (2.09L) is below the 1-week average (2.78L), showing reduced participation. Short-term momentum remains positive, with resistance near ₹1,700–₹1,720.
🎯 Entry Zone: ₹1,590–₹1,610 (support near DMA cluster)
🚪 Exit Zone: ₹1,700–₹1,720 (resistance zone)
🛑 Stop-Loss: ₹1,570 (below support)
📊 Trend Status: Strongly trending upward; possible consolidation if volumes remain weak.
Positive
- Trading above both 50 DMA and 200 DMA confirms bullish trend.
- Strong ROCE (29.4%) and ROE (23.1%) highlight efficiency.
- Debt-to-equity ratio at 0.08 ensures financial stability.
- Sequential PAT growth (₹141 Cr vs ₹113 Cr) shows operational improvement.
- DII holdings increased (+2.17%), reflecting domestic institutional support.
Limitation
- High P/E (51.4) compared to industry PE (43.9) signals overvaluation.
- PEG ratio (2.32) suggests growth is already priced in.
- Volume below average reduces conviction in breakout potential.
- Quarterly profit variation (-4.92%) highlights earnings pressure.
Company Negative News
- Decline in FII holdings (-3.11%) signals reduced foreign investor confidence.
- Profit variation negative despite sequential PAT growth.
Company Positive News
- Sequential PAT growth (₹141 Cr vs ₹113 Cr) reflects operational strength.
- DII inflows (+2.17%) show strong domestic support.
- EPS of ₹30.3 provides valuation backing.
Industry
- Industry PE at 43.9 is lower than LALPATHLAB’s 51.4, highlighting premium valuation.
- Diagnostics and healthcare sector remains resilient, supported by steady demand growth.
Conclusion
⚡ LALPATHLAB is in a strong uptrend with robust technical momentum and solid fundamentals. Entry near ₹1,590–₹1,610 offers favorable positioning, with profit exits around ₹1,700–₹1,720. Elevated valuations and weak volume warrant disciplined risk management, but long-term prospects remain strong given efficiency and sector resilience.
Would you like me to extend this into a diagnostics sector overlay comparing peers like Metropolis and Thyrocare, or keep it focused as a single LALPATHLAB swing trade report?